On Monday analysts at Leerink Swann downgraded Merck & Co., Inc. (MRK) because of market uncertainty with regards to a variety of pharmaceutical products.
The analysts downgraded MRK from “Outperform” to “Market Perform.”
Leerink Swann commented: “(1) reduced prospects with the delay/uncertainty around odanacatib, (2) increasing 2013+ competition vs. Januvia & Isentress as well as the outcome of Germany’s (G-BA/AMNOG) planned assessment of DPP-IV inhibitors, (3) ongoing investor concerns around the Zetia/Vytorin franchise that likely will cap share appreciation until IMPROVE-IT completes either in March 2013 or 2H14, and (4) a relatively high-risk Phase II/III pipeline including anacetrapib (CETP inhibitor) and BACE (Alzheimer’s) that are several years from the market.”
Merck shares were down 48 cents, or -1.15%, during pre-market trading on Monday. The stock is up +9.02% over the past year.
The Bottom Line
Shares of Merck (MRK) have a dividend yield of 4.11% based on Friday’s closing price of $41.83.
Merck & Co., Inc. (MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here